|
Sign In to gain access to subscriptions and/or personal tools.
|
Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study
N C Silver
NMR Research Unit, Institute of Neurology, University College London, UK
P S Tofts
NMR Research Unit, Institute of Neurology, University College London, UK
M R Symms
NMR Research Unit, Institute of Neurology, University College London, UK
G J Barker
NMR Research Unit, Institute of Neurology, University College London, UK
A J Thompson
NMR Research Unit, Institute of Neurology, University College London, UK
D H Miller
NMR Research Unit, Institute of Neurology, University College London, UK
Gadolinium enhanced magnetic resonance imaging detects focal blood-brain barrier breakdown in new inflammatory multiple sclerosis lesions, but such lesions do not correlate with disease progression. To explore whether the latter might relate to subtle but widespread blood-brain barrier (BBB) breakdown with low grade inflammation mediating tissue damage, quantitative techniques were used to detect subtle gadolinium enhancement within otherwise normal-appearing white matter and within lesions not showing visible enhancement. T1-weighted imaging was performed prior to and at 5, 20 and 40 min following injection of 0.3 mmol/kg gadopentate dimeglumine in 33 patients with multiple sclerosis and five healthy control subjects. In healthy controls, a significant increase in white matter signal 5 min following contrast injection was observed (1.8%, P < 0.0005); the signal returned to baseline values by 20 min. In multiple sclerosis patients, a non-significant trend was noted for signal to remain elevated in normal-appearing white matter at the 20 and 40 min post-contrast time points; this was most apparent in primary progressive multiple sclerosis. Significant increases in signal intensity were noted at all time points post contrast in apparent non-enhancing lesions. The transient post contrast signal increase in controls is likely due to intravascular gadopentate dimeglumine. The persistent increases in signal intensity in non-enhancing lesions suggest more widespread abnormalities in BBB than is visually apparent, but substantiation of BBB leakage in normal appearing white matter will require further study using more sensitive methods.
Key Words: multiple sclerosis • magnetic resonance imaging • gadolinium • blood-brain barrier • lesion • normal-appearing white matter
Multiple Sclerosis, Vol. 7, No. 2,
75-82 (2001)
DOI: 10.1177/135245850100700201
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Zeis, U. Graumann, R. Reynolds, and N. Schaeren-Wiemers
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection
Brain,
January 1, 2008;
131(1):
288 - 303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.M. Mitchell, A.L. Dotson, K.M. Cool, A. Chakrabarty, S.H. Benedict, and S.M. LeVine
Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis
Multiple Sclerosis,
November 1, 2007;
13(9):
1118 - 1126.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Marik, P. A. Felts, J. Bauer, H. Lassmann, and K. J. Smith
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?
Brain,
November 1, 2007;
130(11):
2800 - 2815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Soon, D. Tozer, D. Altmann, P. Tofts, and D. Miller
Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes
Multiple Sclerosis,
August 1, 2007;
13(7):
884 - 894.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Kutzelnigg, C. F. Lucchinetti, C. Stadelmann, W. Bruck, H. Rauschka, M. Bergmann, M. Schmidbauer, J. E. Parisi, and H. Lassmann
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Brain,
November 1, 2005;
128(11):
2705 - 2712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans, M. Clanet, E. W. Radue, L. Kappos, and for the European IFNss-1a in Relapsing MS Dose Com
Rate of brain atrophy in relapsing MS decreases during treatment with IFN{beta}-1a
Neurology,
January 25, 2005;
64(2):
236 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.M. Leary, D.H. Miller, V.L. Stevenson, P.A. Brex, D.T. Chard, and A.J. Thompson
Interferon {beta}-1a in primary progressive MS: An exploratory, randomized, controlled trial
Neurology,
January 14, 2003;
60(1):
44 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wolinsky
MRI aspects of secondary progressive multiple sclerosis
Multiple Sclerosis,
September 1, 2002;
8(1_suppl):
85 - 87.
[PDF]
|
|
|
|
|
|
|
D. H. Miller, F. Barkhof, J. A. Frank, G. J. M. Parker, and A. J. Thompson
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
Brain,
August 1, 2002;
125(8):
1676 - 1695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J S Wolinsky
MRI aspects of secondary progressive multiple sclerosis
Multiple Sclerosis,
February 1, 2002;
8(1):
85 - 87.
[PDF]
|
|
|
|
|
|
|
M. Rovaris, M. Bozzali, G. Santuccio, A. Ghezzi, D. Caputo, E. Montanari, A. Bertolotto, R. Bergamaschi, R. Capra, G. Mancardi, et al.
In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis
Brain,
December 1, 2001;
124(12):
2540 - 2549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
